Company news
Kissei Pharmaceutical Co., Ltd. (TSE:4547) news
Every Kissei Pharmaceutical Co., Ltd. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Notice of Completion of Payment for Treasury Shares Disposal as Restricted Stock for Employee Shareholding Association and Partial
August 10, 2026
Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
July 31, 2026
Notice Regarding Completion of Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
July 23, 2026
Announcement for the Opnion by European Authorities on TAVNEOS
June 28, 2026
Notice Concerning Disposal of Treasury Shares as Restricted Stock for Members of the Board and Corporate Officers
June 23, 2026
Notice Concerning Status of Acquisition of Treasury Shares
June 3, 2026
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment
October 7, 2025
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
August 6, 2025
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update
August 5, 2025
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
July 30, 2025
Kissei Pharmaceutical : The Opening of a new Office for Open Innovation in the Boston Area
April 1, 2025
Kissei Pharmaceutical : Initiates Phase III Clinical Trial for GnRH Antagonist "Linzagolix" Indicated for Endometriosis
March 31, 2025
Kissei Pharmaceutical : Initiates Additional Phase III Clinical Trial for Rovatirelin (KPS-0373) for the Treatment of Spinocerebellar Degeneration
March 14, 2025
Kissei Pharmaceutical : Marketing Authorization for the Oral Spleen Tyrosine Kinase Inhibitor TAVALISSE® in South Korea
January 20, 2025
Kissei Pharmaceutical : Notice Concerning the Results of the Acquisition of Treasury Shares, Through Off Auction Treasury Share Repurchase Trading System (ToSTNeT 3), the Completion of Acquisition of Treasury shares and the Cancellation of Treasury Shares
November 5, 2024
Kissei Pharmaceutical : Notice on the Acquisition of Treasury Shares, the Acquisition of Treasury Shares Through Off Auction Own Share Repurchase Trading System (ToSTNeT 3) and the Cancellation of Treasury Shares
November 5, 2024
Kissei Pharmaceutical : Succession of Manufacturing and Marketing Authorization for MARIZEV®, Diabetes Treatment
September 24, 2024
Kissei Pharmaceutical : Launch of YSELTY® (generic name linzagolix) for uterine fibroid treatment in Europe
September 16, 2024
Kissei Pharmaceutical : Notice Concerning Status of Acquisition and Completion of the Company's Own Shares
March 19, 2024
Kissei Pharmaceutical : Notice Concerning Status of Acquisition of the Company's Own Shares
March 1, 2024
Kissei Pharmaceutical : KORSUVA® IV Injection Syringe for Dialysis 17.5μg, 25.0μg and 35.0μg to Launch in Japan for Treatment of Pruritus in Patients Undergoing Hemodialysis
December 12, 2023
Kissei Pharmaceutical : Notice Concerning Revisions to Financial Results Forecast
October 26, 2023
Kissei Pharmaceutical : Results of Japanese Phase III Clinical Study of KORSUVA® IV Injection for Pruritus in Patients undergoing Hemodialysis Published in NEJM Evidence
October 22, 2023
Kissei Pharmaceutical : Supplementary Explanatory Materials on Financial Results for the Three Months ended June 30, 2022
August 5, 2022
Kissei Pharmaceutical : Consolidated Financial Results for the Three Months Ended June 30, 2022
August 5, 2022
Kissei Pharmaceutical : Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib
October 29, 2018
Kissei Pharmaceutical : Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia
May 30, 2018
Kissei Pharmaceutical : Announces New President and COO
April 23, 2018
Kissei Pharmaceutical : JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study
January 17, 2018
Kissei Pharmaceutical : Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" Launches in Japan
December 6, 2017
Kissei Pharmaceutical : Marketing Approval for Ulcerative Colitis Treatment "RECTABUL® 2 mg Rectal Foam 14 Doses" was Obtained in Japan
September 27, 2017